Karin Hedin
The liver plays a central role in human metabolism, yet significant gaps remain in understanding how its function is altered in disease. Metabolic dysfunction-associated steatotic liver disease (MASLD), affecting approximately 30% of the global population, is the most prevalent chronic liver condition. As a multisystemic disorder, MASLD is linked to increased risks of cardiovascular disease and metabolic comorbidities. A subset of patients progresses to hepatic fibrosis, heightening the risk of liver-related complications.
The pathogenesis of fibrosis and progression to metabolic dysfunction-associated steatohepatitis (MASH) remains poorly understood, complicating early identification of high-risk individuals. My research focuses on characterizing metabolic alterations in MASLD to identify biomarkers predictive of fibrosis, aiming to refine clinical phenotyping and improve prognostic accuracy.